IS4951A - Lyfjablanda sem er andsegavirk og vinnur gegn myndun fituskellu í slagæð sem inniheldur þíenópýridínafleiðu og HMG-CoA redúktasahemil - Google Patents

Lyfjablanda sem er andsegavirk og vinnur gegn myndun fituskellu í slagæð sem inniheldur þíenópýridínafleiðu og HMG-CoA redúktasahemil

Info

Publication number
IS4951A
IS4951A IS4951A IS4951A IS4951A IS 4951 A IS4951 A IS 4951A IS 4951 A IS4951 A IS 4951A IS 4951 A IS4951 A IS 4951A IS 4951 A IS4951 A IS 4951A
Authority
IS
Iceland
Prior art keywords
hmg
counteracts
formation
coa reductase
reductase inhibitor
Prior art date
Application number
IS4951A
Other languages
English (en)
Other versions
IS2052B (is
Inventor
Daste Georges
Herbert Jean-Marc
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of IS4951A publication Critical patent/IS4951A/is
Publication of IS2052B publication Critical patent/IS2052B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
    • F16K41/00—Spindle sealings
    • F16K41/02—Spindle sealings with stuffing-box ; Sealing rings
    • F16K41/04—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing
    • F16K41/043—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles
    • F16K41/046—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles for rotating valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02D—CONTROLLING COMBUSTION ENGINES
    • F02D9/00—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits
    • F02D9/04—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits concerning exhaust conduits
    • F02D9/06—Exhaust brakes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
    • F16K1/00—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces
    • F16K1/16—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members
    • F16K1/18—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps
    • F16K1/22—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps with axis of rotation crossing the valve member, e.g. butterfly valves

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Combustion & Propulsion (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS4951A 1996-07-26 1999-01-22 Lyfjablanda sem er andsegavirk og vinnur gegn myndun fituskellu í slagæð sem inniheldur þíenópýridínafleiðu og HMG-CoA redúktasahemil IS2052B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609474A FR2751540B1 (fr) 1996-07-26 1996-07-26 Composition pharmaceutique antithrombotique
PCT/FR1997/001353 WO1998004259A1 (fr) 1996-07-26 1997-07-21 COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE

Publications (2)

Publication Number Publication Date
IS4951A true IS4951A (is) 1999-01-22
IS2052B IS2052B (is) 2005-10-14

Family

ID=9494551

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4951A IS2052B (is) 1996-07-26 1999-01-22 Lyfjablanda sem er andsegavirk og vinnur gegn myndun fituskellu í slagæð sem inniheldur þíenópýridínafleiðu og HMG-CoA redúktasahemil

Country Status (35)

Country Link
US (1) US6218403B1 (is)
EP (1) EP0914124B1 (is)
JP (1) JP3553610B2 (is)
KR (1) KR100307268B1 (is)
CN (1) CN1109547C (is)
AR (1) AR008782A1 (is)
AT (1) ATE258052T1 (is)
AU (1) AU725949B2 (is)
BR (1) BR9710560B1 (is)
CA (1) CA2261099C (is)
CZ (1) CZ294664B6 (is)
DE (1) DE69727299T2 (is)
DK (1) DK0914124T3 (is)
EE (1) EE03853B1 (is)
ES (1) ES2214632T3 (is)
FR (1) FR2751540B1 (is)
HK (1) HK1019405A1 (is)
HU (1) HU226245B1 (is)
ID (1) ID17774A (is)
IL (1) IL128102A0 (is)
IS (1) IS2052B (is)
MY (1) MY125051A (is)
NO (1) NO322894B1 (is)
NZ (1) NZ333826A (is)
PL (1) PL188739B1 (is)
PT (1) PT914124E (is)
RS (1) RS49504B (is)
RU (1) RU2176504C2 (is)
SI (1) SI0914124T1 (is)
SK (1) SK284944B6 (is)
TR (1) TR199900154T2 (is)
TW (1) TW442289B (is)
UA (1) UA58518C2 (is)
WO (1) WO1998004259A1 (is)
ZA (1) ZA976247B (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
KR100839136B1 (ko) * 2001-12-18 2008-06-20 테바 파마슈티컬 인더스트리즈 리미티드 클로피도그렐 황산수소염의 다형
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
US20060178424A1 (en) * 2003-06-18 2006-08-10 Stanley Nattel Preventing atrial fibrillation (af) with the use of stain drugs
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
KR100563455B1 (ko) * 2004-04-09 2006-03-23 한미약품 주식회사 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
JP5179354B2 (ja) * 2005-09-15 2013-04-10 大塚製薬株式会社 スーパーオキサイド抑制効果を有するプロブコールおよびテトラゾリルアルコキシ−ジヒドロカルボスチリル誘導体を含む併用薬
PL2007362T3 (pl) * 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
CA2655844A1 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Process for preparing clopidogrel bisulphate
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
CA2683611A1 (en) * 2007-04-09 2008-10-16 Usv Limited Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
WO2008129468A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of clopidogrel
EP2152078B8 (en) * 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
WO2010009745A1 (en) * 2008-07-25 2010-01-28 Pharmathen S.A. Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
BRPI1009600A2 (is) 2009-06-25 2016-03-22 Tetra S A
RU2461379C2 (ru) * 2010-12-09 2012-09-20 Закрытое акционерное общество "ФАРМ-ЦЕНТР" (ЗАО "ФАРМ-ЦЕНТР") Фармацевтическая комбинация, обладающая антиагрегантной и липидрегулирующей активностями, фармацевтическая композиция
BR112019015107A2 (pt) 2017-01-23 2020-03-10 Dong Wha Pharm. Co., Ltd. Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
WO1995011898A1 (en) * 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke

Also Published As

Publication number Publication date
HUP9903752A2 (hu) 2000-03-28
JP2000500781A (ja) 2000-01-25
EE9900028A (et) 1999-08-16
ES2214632T3 (es) 2004-09-16
SK284944B6 (sk) 2006-03-02
DK0914124T3 (da) 2004-05-17
SI0914124T1 (en) 2004-06-30
PT914124E (pt) 2004-05-31
SK7899A3 (en) 1999-07-12
UA58518C2 (uk) 2003-08-15
HUP9903752A3 (en) 2001-12-28
NZ333826A (en) 2000-09-29
KR100307268B1 (ko) 2001-09-24
PL331339A1 (en) 1999-07-05
JP3553610B2 (ja) 2004-08-11
RU2176504C2 (ru) 2001-12-10
CZ294664B6 (cs) 2005-02-16
BR9710560A (pt) 1999-08-17
EP0914124A1 (fr) 1999-05-12
NO990321D0 (no) 1999-01-25
CA2261099C (fr) 2003-04-15
MY125051A (en) 2006-07-31
WO1998004259A1 (fr) 1998-02-05
AU725949B2 (en) 2000-10-26
FR2751540B1 (fr) 1998-10-16
PL188739B1 (pl) 2005-04-29
ATE258052T1 (de) 2004-02-15
HU226245B1 (en) 2008-07-28
CN1109547C (zh) 2003-05-28
TR199900154T2 (xx) 1999-04-21
RS49504B (sr) 2006-10-27
US6218403B1 (en) 2001-04-17
NO322894B1 (no) 2006-12-18
DE69727299D1 (de) 2004-02-26
IS2052B (is) 2005-10-14
NO990321L (no) 1999-03-22
AR008782A1 (es) 2000-02-23
BR9710560B1 (pt) 2013-12-03
IL128102A0 (en) 1999-11-30
HK1019405A1 (en) 2000-02-11
ID17774A (id) 1998-01-29
YU3199A (sh) 2002-09-19
CA2261099A1 (fr) 1998-02-05
EE03853B1 (et) 2002-10-15
FR2751540A1 (fr) 1998-01-30
CZ17699A3 (cs) 1999-05-12
ZA976247B (en) 1999-01-15
KR20000029484A (ko) 2000-05-25
DE69727299T2 (de) 2004-10-21
AU3852697A (en) 1998-02-20
TW442289B (en) 2001-06-23
EP0914124B1 (fr) 2004-01-21
CN1228698A (zh) 1999-09-15

Similar Documents

Publication Publication Date Title
IS4951A (is) Lyfjablanda sem er andsegavirk og vinnur gegn myndun fituskellu í slagæð sem inniheldur þíenópýridínafleiðu og HMG-CoA redúktasahemil
NO20006451D0 (no) Inhibitorer av transkripsjonsfaktor NF-kB
PL340579A1 (en) Method of obtaining derivatives of taxoids class
PL331047A1 (en) Novel amidinic derivatives and their application as inhibitors of thrombosin
FI980043A (fi) Ääntä vaimentava tuote ja menetelmä sen valmistamiseksi
NO982809D0 (no) Prolegemidler av tombin-inhibitorer
EE200300169A (et) Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69805334T2 (de) Derivate des vitamin e
NO20006452D0 (no) Inhibitorer av transkripsjonsfaktor NF-kB
HUP0100743A3 (en) Process for preparation of simvastatin and derivatives thereof
FR2791571B1 (fr) Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
FI980269A (fi) Menetelmä norborneenin ja sen johdannaisten syntetisoimiseksi
NO996183D0 (no) Fremgangsmåte for fremstilling av medikamenter som innbefatter HMG-CoA-reduktaseinhibitorer
NO992861D0 (no) Et oljepreparat av dihydropolyprenoler
TW468579U (en) Structure of sounding and lighting wheel
PL351128A1 (en) Method of obtaining phenoglycine and derivatives thereof
IS4842A (is) Hlutar í innúðatæki
AU2293700A (en) Inhibitors for the biosynthesis of vitamin b2 and method for producing same
KR980003762U (ko) 제품 브랜드의 고정 장치
PL335149A1 (en) Method of obtaining polycyclic compounds and application of initial compound
KR960035334U (ko) 장식효과 및 안경알의 분리방지를 위한 미미카바
PL329663A1 (en) Novel peptide derivatives of analgesic properties and method of obtaining them
EP1007076A4 (en) PROCESS FOR ANTAGONIZING THE HUMAN DOMAIN SRC SH2